Dermatologic therapeutics: Thalidomide. A practical guide

Dermatologic Therapy

Volumn 20, Issue 4, 2007, Pages 175-186

  Rosenbach, M ^a   Werth, Victoria P ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Philadelphia VA Medical Center   (United States)

^c 2 Rhodes Pavilion ^*  (United States)

Author keywords

Dermatologic use; Dermatology; Guidelines; Thalidomide

Indexed keywords

CYCLOOXYGENASE 2; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 C19; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 5; PLACEBO; PREDNISONE; TEMOZOLOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTINIC PRURIGO; ACUTE GRANULOCYTIC LEUKEMIA; ADULT ONSET STILL DISEASE; AMENORRHEA; ANTIINFLAMMATORY ACTIVITY; APHTHOUS STOMATITIS; BEHCET DISEASE; BRADYCARDIA; BREAST CANCER; CACHEXIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL PRACTICE; COLORECTAL CANCER; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONGESTIVE HEART FAILURE; CONSTIPATION; CROHN DISEASE; DERMATOLOGY; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; EDEMA; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM LEPROSUM; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HEAD AND NECK CARCINOMA; HELPER CELL; HISTIOCYTOSIS X; HODGKIN DISEASE; HUMAN; HYPERESTHESIA; HYPESTHESIA; HYPOTENSION; INCREASED APPETITE; JESSNER LYMPHOCYTIC INFILTRATION; JUVENILE RHEUMATOID ARTHRITIS; KAPOSI SARCOMA; KIDNEY CARCINOMA; LANGERHANS CELL; LEIOMYOBLASTOMA; LICHEN PLANUS; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MALE SEXUAL DYSFUNCTION; MELANOMA; MOOD CHANGE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID LEUKEMIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL; NONHUMAN; OVARY CANCER; OVARY INSUFFICIENCY; PARESTHESIA; PRACTICE GUIDELINE; PROSTATE CANCER; PRURIGO; PRURIGO NODULARIS; PRURITUS; PYODERMA GANGRENOSUM; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SCLEROMYXEDEMA; SEDATION; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SPONDYLOARTHROPATHY; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TERATOGENICITY; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UREMIA; UREMIC PRURITUS; WALDENSTROEM MACROGLOBULINEMIA; WASTING SYNDROME; WEIGHT GAIN; XEROSIS;

ANIMALS; HUMANS; PRACTICE GUIDELINES AS TOPIC; SKIN DISEASES; THALIDOMIDE;

EID: 35648950555     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00132.x     Document Type: Review

References (101)

1. Mellin GW, Katzenstein M. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital abnormalities. N Engl J Med 1962 : 267 : 1184 1193.
2. Stirling D, Sherman M, Strauss S. Thalidomide. A surprising recovery. J Am Pharm Assoc 1997 : NS37 : 306 313.
3. Randall T. Thalidomide has 37-year history. J Am Med Assoc 1990 : 263 : 1474.
4. Kelsey FO. Thalidomide update: regulatory aspects. Teratology 1988 : 38 : 221 226.
5. Mellin GW. The saga of thalidomide (concluded). N Engl J Med 1962 : 267 : 1238 1244.
6. Lenz W. A short history of thalidomide embryopathy. Teratology 1988 : 38 : 203 215.
7. McBride WG. Thalidomide and congenital abnormalities (Letter to the editor). Lancet 1961 : 2 : 1358.
8. Tansey EM. Dark remedy. The impact of thalidomide and its revival as a vital medicine. Book review. N Engl J Med 2001 : 345 : 226 227.
9. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965 : 6 : 303 306.
10. Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis 1969 : 37 : 135 146.
11. Thalomid capsules [package insert]. Warren, NJ : Celgene Corporation, 2001.
12. Wnendt S, Finkam M, Winter W, Ossig J, Raabe G, Zwingenberger K. Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues. Chirality 1996 : 8 : 390 396.
13. Frederickson RC, Slater IH, Dusenberry WE, Hewes CR, Jones GT, Moore RA. A comparison of thalidomide and pentobarbital: new methods for identifying novel hypnotic drugs. J Pharmacol Exp Ther 1977 : 203 : 240 251.
14. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984 : 23 : 598 602.
15. Teo SK, Scheffler Mr Kook KA, et al. Thalidomide dose proportionality assessment following single doses to healthy subjects. J Clin Pharmacol 2001 : 41 : 662 667.
16. Teo SK, Scheffler MR, Kook KA, et al. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharm Drug Dispos 2000 : 21 : 33 40.
17. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003 : 23 : 342 395.
18. Teo SK, Harden JL, Burke AB, et al. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos 2001 : 29 : 1355 1357.
19. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998 : 55 : 1827 1834.
20. Franks ME, Macphreson GR, Figg WD. Thalidomide. Lancet 2004 : 363 : 1802 1811.
21. Trapnell CB, Donahue SR, Collins JM, Flockhart DA, Thacker D, Abernethy DR. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther 1998 : 64 : 597 602.
22. Scheffler MR, Colburn W, Kook KA, Thomas SD. Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics. Clin Pharmacol Ther 1999 : 65 : 483 490.
23. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991 : 173 : 699 703.
24. Moreira Al Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993 : 177 : 1675 1680.
25. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 1980 : 269 : 275 280.
26. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002 : 130 : 75 84.
27. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of TNF-alpha and IL-1 beta during leprosy reactional states. Clin Exp Immunol 1991 : 84 : 103 108.
28. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995 : 99 : 160 167.
29. Verbon A, Juffermans NP, Speelman P, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother 2000 : 44 : 2286 2290.
30. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997 : 159 : 5157 5161.
31. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T-cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999 : 163 : 380 386.
32. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001 : 98 : 210 216.
33. Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 1985 : 56 : 35 39.
34. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994 : 91 : 4082 4085.
35. Stephens TS, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000 : 59 : 1489 1499.
36. Singhal S, Mehta J. Thalidomide in cancer: potential uses and limitations. Biodrugs 2001 : 15 : 163 172.
37. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001 : 7 : 3349 3355.
38. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NFB activity by thalidomide through suppression of IB kinase activity. J Biol Chem 2001 : 276 : 22382 22387.
39. Browne SG. Erythema nodosum in leprosy. J Chronic Dis 1963 : 16 : 23 30.
40. Iyer CG, Languillon J, Ramanujam K, et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 1971 : 45 : 719 732.
41. Sheskin J. The treatment of lepra reaction in lepromatous leprosy: fifteen years experience with thalidomide. Int J Dermatol 1980 : 19 : 318 322.
42. Crawford CL. Use of thalidomide in leprosy. Adverse Drug React Toxicol Rev 1994 : 13 : 177 192.
43. Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. Arch Dermatol 1979 : 115 : 636 637.
44. Revuz J, Guillaume JC, Janier M et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990 : 126 : 923 927.
45. Torras H, Lecha M, Mascaro JM. Thalidomide treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosis. Arch Dermatol 1982 : 118 : 875.
46. Jenkins JS, Powell RJ, Allen BR, Littlewood SM, Maurice PD, Smith NJ. Thalidomide in severe orogenital ulceration. Lancet 1984 : ii : 1424 1426.
47. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol 1985 : 12 : 85 90.
48. Ranselaar CG, Boone RM, Kluin-Nelemans HC. Thalidomide in the treatment of neuro-Behçet's syndrome. Br J Dermatol 1986 : 115 : 367 370.
49. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997 : 336 : 1487 1493.
50. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. J Infect Dis 2001 : 183 : 343 346.
51. Tseng S, Pak G. Rediscovering thalidomide. A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996 : 35 : 969 979.
52. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome. Arch Dermatol 1982 : 118 : 536.
53. Hamza MH. Treatment of Behçet's disease with thalidomide. Clin Rheumatol 1986 : 5 : 365 371.
54. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998 : 128 : 443 450.
55. De Wazieres B, Gil H, Magy N, Berthier S, Vuitton DA, Dupond JL. Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients. Rev Med Interne 1999 : 20 : 567 570.
56. Kari JA, Shah V, Dillon MJ. Behçet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology 2001 : 40 : 933 938.
57. Soler RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996 : 23 : 504 505.
58. Fife K, Howard MR, Gracie F, Phillips RH, Bower M. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998 : 9 : 751 755.
59. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000 : 18 : 2593 2602.
60. Johnke H, Zachariae H. Thalidomide treatment of prurigo nodularis. Ugeskr Laeger 1993 : 155 : 3028 3030.
61. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2004 : 153 : 254 273.
62. Ferrandiz C, Carrascosa JM, Just M, Bielsa I, Ribera M. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. Dermatology 1997 : 195 : 359 361.
63. Stirling DI. Thalidomide and its impact in dermatology. Semin Cutan Med Surg 1998 : 17 : 231 242.
64. Londono F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973 : 12 : 326 328.
65. Lovell CR, Hawk JL, Calnan CD, Magnus IA. Thalidomide in actinic prurigo. Br J Dermatol 1983 : 108 : 467 471.
66. Gnassia AM, Gnassia RT, Bonvalet D. Histiocytose X avec "granulome eosinophile vulvaire": effet spectaculaire de la thalidomide. Ann Dermatol Venereol 1987 : 114 : 1387 1389.
67. Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994 : 67 : 270 273.
68. Buckley C, Sarkany I, Bayoumi AH. Pyoderma gangrenosum with severe pharyngeal ulceration. J R Soc Med 1990 : 83 : 590 591.
69. Farrell AM, Black MM, Bracka A, Bunker CB. Pyoderma gangrenosum of the penis. Br J Dermatol 1998 : 138 : 337 340.
70. Moulin G, Bonnet F, barrut D, Franc MP. Treatment of Jessner-Kanof disease with thalidomide. Ann Dermatol Venereol 1983 : 110 : 611 614.
71. Guillaume JC, Moulin G, Dieng MT, et al. Crossover study of thalidomide vs. placebo in Jessner's lymphocytic infiltration of the skin. Arch Dermatol 1995 : 131 : 1032 1035.
72. English JC III, Patel PJ, Greer KE. Sarcoidosis. J Am Acad Dermatol 2001 : 44 : 725 743.
73. Barriere H. Sarcoides cutanées. Traite par la thalidomide. Presse Med 1983 : 12 : 963.
74. Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002 : 102 : 225 236.
75. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995 : 32 : 866 869.
76. Bahmer FA, Zaun H, Luszpinski P. Thalidomide treatment of recurrent erythema multiforme. Acta Derm Venereol (Stockh) 1982 : 62 : 449 450.
77. Cherouati K, Claudy A, Souteyrand P, et al. Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients. Ann Dermatol Venereol 1996 : 123 : 375 377.
78. Lim SH, McWhannell A, Vora AJ, Boughton BJ. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet 1988 : i : 117.
79. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992 : 326 : 1055 1058.
80. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001 : 7 : 265 273.
81. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996 : 2 : 86 92.
82. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000 : 96 : 3995 3996.
83. Hwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005 : 103 : 2590 2597.
84. Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian, and breast cancer. Br J Cancer 2000 : 82 : 812 817.
85. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984 : 23 : 598 602.
86. Pelle MT, Werth VP. Thalidomide in vutaneous lupus erythematosus. Am J Clin Dermatol 2003 : 4 : 379 387.
87. Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000 : 97 : 109 120.
88. Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Derm 2004 : 140 : 277 280.
89. Sansbury JC, Cocuroccia B, Jorizzo JL, Gubinelli E, Gisondi P, Girolomoni G. Treatment of recalcitrant scleromyxedema with thalidomide in three patients. J Am Acad Dermatol 2004 : 51 : 126 131.
90. Klausner JD, Kaplan G, Haslett PA. Thalidomide in toxic epidermal necrolysis. Lancet 1999 : 353 : 324.
91. Piette JC, Sbaj A, Frances C. Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus. Lupus 2002 : 11 : 67 70.
92. Camba L, Peccatori J, Pescarollo A, Tresoldi M, Corradini P, Bregni M. Thalidomide and thrombosis in patients with multiple myeloma. Haematologica 2001 : 86 : 1108 1109.
93. Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L. Thalidomide et thromboses. Ann Dermatol Venerol 2000 : 127 : 171 174.
94. Howe P. Neuropathy after thalidomide ("Distaval") [letter]. Br Med J 1961 : 2 : 1084.
95. Heathfield KWG. Neuropathy after thalidomide ("Distaval"). Br Med J 1961 : 2 : 1084.
96. Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002 : 119 : 1020 1026.
97. Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994 : 130 : 66 69.
98. Clemmenson OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984 : 120 : 338 341.
99. Ordi J, Cortes F, Martinez N, Mauri M, De Torres I, Vilardell M. Concise communication: thalidomide induces amenorrhea in patients with lupus disease. Arthritis Rheum 1998 : 41 : 2273 2275.
100. Dharia SP, Steinkampf MP, Cater C. Thalidomide-induced amenorrhea: case report and literature review. Fertil Steril 2004 : 82 : 460 462.
101. Zeldis JB, Williams BA, Thomas SD, Elsayed MESTEPS : a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999 : 21 : 319 330.